Immunic (IMUX) Other Non-Current Liabilities (2013 - 2019)

Immunic (IMUX) posted Other Non-Current Liabilities of $41000.0 for Q3 2019, little changed sequentially from $41000.0 in Q2 2019.

Analysis

Immunic (IMUX) Other Non-Current Liabilities (2013 - 2019) Analysis & Trends

Immunic has reported Other Non-Current Liabilities for 4 years, with the latest figure at $41000.0 in Q3 2019.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $41000.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $41000.0 (changed N/A YoY) and the FY2015 annual result came in at $101000.0, down 58.09% from the prior year.
Other Non-Current Liabilities held at $41000.0 in Q3 2019 per IMUX's latest filing, from $41000.0 in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $200000.0 in Q1 2015 and troughed at $41000.0 in Q2 2019.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.51 Bn	130.66 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.24 Bn	77.25 Bn	3.93 Bn
3	Argenx Se	63.46 Bn	58.28 Bn	1.37 Bn
4	Moderna	57.89 Bn	52.75 Bn	52.00 Mn
5	Revolution Medicines	44.02 Bn	44.02 Bn	-
6	BeOne Medicines	39.95 Bn	34.85 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.49 Bn	32.19 Bn	992.69 Mn
8	Royalty Pharma	28.43 Bn	27.59 Bn	-
9	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
10	Immunic	540.78 Mn	540.78 Mn	-

Historic Data

Download Data